Selvita Signs A Significant Collaboration With UCSF

Kraków, Poland, August 9, 2016 / B3C newswire / -- Selvita Inc., the US subsidiary of Selvita S.A., headquartered in Cambridge, MA, has initiated a medicinal chemistry collaboration with the University of California, San Francisco (UCSF). The project will be conducted with the Institute for Neurodegenerative Diseases at UCSF. Within the scope of the project, Selvita will be responsible for the chemical synthesis, purification, structure determination, and purity analysis of small molecules for the treatment of neurodegenerative diseases. The project will focus on the synthesis of new derivatives, constituting potential new therapeutics with improved pharmacological properties.

This project was preceded by a thorough evaluation and pilot projects involving medicinal chemistry as well as ADME projects, which Selvita successfully completed.

The contract will be carried out from 2016 to 2019.

“We’re truly delighted that such renowned research institutions as the Institute for Neurodegenerative Diseases and the University of California have decided to collaborate with Selvita on this project. This is a great chance for us to show the potential of our scientists, as well as the expertise and capabilities we have as a company,” said Andrzej Nieradka, Business Development Manager at Selvita Inc., who is responsible for managing the collaboration.

Selvita’s San Francisco Bay Area office was founded in San Bruno, CA in September 2015 and is dedicated to the support of Selvita business partners on the West Coast of the US. The office is located at 1001 Bayhill Drive, San Bruno, California.

About Selvita

Selvita is a drug discovery company engaged in the research and development of breakthrough therapies in the area of oncology, as well as provision of integrated drug discovery services. Selvita was established in 2007 and currently employs over 340 people, including 111 PhDs, with extensive experience in the area of life sciences. Selvita currently has several projects at both early and late discovery stage and is expected to move its first candidates to the clinic in 2016. Selvita’s drug discovery clients include more than fifty large and medium-sized pharmaceutical and biotechnology companies from the US and Europe. Selvita offices are located in the Greater Boston Area, the San Francisco Bay Area, Cambridge, UK, as well as in Krakow and Poznan, Poland. The company is listed on the Warsaw Stock Exchange (WSE:SLV).

Back to news